Previous 10 | Next 10 |
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Valoctocogene Roxaparvovec MAA Granted Request for Accelerated Assessment PR Newswire SAN RAFAEL, Calif. , June...
Mario13/E+ via Getty Images Eli Lilly (LLY), Seagen (SGEN), and BioMarin Pharmaceutical (BMRN) have been picked as top large-cap pharma names at Bank of America. Their growing/ stable core businesses have “the potential for transformational developments” by 2021 year-end, accord...
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close European Commission Decision expected Q3 2021 Temporary Authorization for Use (ATU) Granted in France to Allow Access and R...
FDA approval of Biogen’s Aduhelm for Alzheimer’s should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The rerating of Biogen shares following the FDA decision demonstrates the ...
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference PR Newswire SAN RAFAEL, Calif. , June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Secu...
BioMarin product revenue has begun to decline. The outlook and guidance for 2021 is consistent with the modest decline reported in the first quarter. The next catalyst is likely November 2021 which is the scheduled PDUFA date for Vosoritide. Roctavian remains the most signifi...
BioMarin stock remains depressed since the August CRL. There are major catalysts ahead. BMRN has a solid cash balance and revenue stream. For further details see: BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead
Sangamo and licensee Pfizer's SB-525 is competing with BioMarin's ValRox in hemophilia A. There are durability questions surrounding both drugs. However, they will have a positive role to play in this indication. For further details see: Sangamo's Hemophilia A Treatment:...
BioMarin Pharmaceutical (BMRN) announces that the EMA has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A.Accelerated assessment reduces the time frame for the EMA's advisory groups to review a marketing authorization applicati...
European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A MAA Resubmission on Track for June 2021 PR Newswire SAN RAFAEL, Calif. , May 24, 2021 /PRNewswire/ -- BioMarin Ph...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...